Viewing Expert Gordon Reid | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Viewing Expert

Gordon Reid , President

GoodReid Investment Counsel

Address
47 Colborne Street
Suite 400
Toronto, ON
M5E 1P8

Contact Info
Telephone: 416.364.0890
Toll Free: 1.888.466.3734
Fax: 416.364.1788
Email:


Date Signal Chart Symbol Company Opinion Price
2016-06-15 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Markets. The Fed lowered the expectation for future rate hikes, and the market didn’t like it. It clearly said it was worried about the economy. Historically the Fed has had a very, very poor record of being able to anticipate what the economy will do. He does what he has always done which is to create balanced portfolios for clients. The process is not to expect to be right all the time, it is to minimize losses to a point where you outperform markets, or the opportunities that other investors have versus yourself. If you can do that, then you will add value, the buying power will be better, and economically their life will be better.


Price:
$0.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
_N/A
2016-06-15 SELL Must be logged in to use chart ABBV-N AbbVie Inc.

This is a result of a spinoff from Abbott Labs 2 or 3 years ago, and they took the pharmaceutical portion, which consisted primarily of 1 drug, Humira. That drug makes up 60%-65% of their revenue, which gives him great pause. Companies, where a large percentage of their revenues are based on one product is a worry. Believes the Humira patent comes off in a couple of years.


Price:
$60.400
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 BUY Must be logged in to use chart BA-N Boeing

You don’t want to completely downplay the SEC issues, but these are complex and accounting processes. The company is doing extremely well. The nice thing is that there is a fair bit of visibility. They are at a stage in the process of the 787 and 737 Max, where they are in full production, so it is really a cash flow story. Not trading at extreme valuations and there is a fair amount of predictability of the runway. Thinks there is visibility out to the end of the decade.


Price:
$130.160
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-06-15 COMMENT Must be logged in to use chart BAC-N Bank of America

All banks are going to be affected by the major macro issues of the federal reserve’s monetary policy, and are all basically in the same boat. They are earning money, loan growth is slow but growing, and assets are growing. The thing that is going to allow them to really do well is a steepening of the yield curve, because that increases margins. This is a good core position.


Price:
$13.340
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-06-15 TOP PICK Must be logged in to use chart C-N CitiGroup

Trading at 64% of tangible book, which gives some downside protection. When a stock is trading on a valuation basis as inexpensively as this one is, it does provide you some comfort that you can stick it out for the longer-term and you are not going to fall too far. Dividend yield of 0.48%.


Price:
$42.010
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-06-15 SELL Must be logged in to use chart COST-Q Costco Wholesale

(Market Call Minute.) They do good things, but just too expensive.


Price:
$154.860
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 SELL Must be logged in to use chart CSCO-Q Cisco

Looking at this company’s financial statements, you will see that revenues, cash flow, earnings have basically flat lined for many years. It was a growth stock at one point, became commoditized to a degree, and then competition started to steal share.


Price:
$28.650
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 BUY Must be logged in to use chart CVS-N CVS Health Corp

A drugstore chain, but it also has a Pharmacy Benefits Manager (PBM) aspect to it. That aspect is very profitable for them, and represents about a 3rd of their business. They are also quite acquisitive having just bought Omnicare, a pharmacy group that concentrates on nursing homes. A profitable and growing area.


Price:
$96.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-06-15 SELL Must be logged in to use chart F-N Ford Motor

(Market Call Minute.) He wouldn’t be a buyer here, but has a great respect for management.


Price:
$13.010
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 SELL Must be logged in to use chart GE-N General Electric

(Market Call Minute.) He wasn’t happy with their Austin deal. It was highly diluted through political influence.


Price:
$30.590
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 COMMENT Must be logged in to use chart GLD-N SPDR Gold ETF

This basically tracks gold. He views gold as a complement to an asset class. If a client of his is looking for some insurance, and wants to protect against extreme outlier events, then a component of gold is something he would not argue against. The statistical likelihood of an outlier event occurring would lead you to only buy a small amount.


Price:
$123.680
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-06-15 SELL Must be logged in to use chart GM-N General Motors Corporation

Basically auto companies haven’t really done anything from a price standpoint, because people think we are at the end of the cycle. PE is quite low which people generally like. However, different sectors and industries react differently to different metrics. A cyclical with a low PE generally is a negative, because it means it is topped out. You want to buy cyclicals when they have high PE ratios, meaning they are about to come out of their negative period when they are not earning any money. He is not a big fan of autos at this point.


Price:
$28.860
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-06-15 DON'T BUY Must be logged in to use chart JNJ-N Johnson & Johnson

Involved in a number of different areas including devices, consumer products and pharmaceuticals. Pharmaceuticals have grown to a point where they represent about half the business. The other 2 are pretty much equally split. The area they have really fallen down on is their hepatitis C drug, which has just not competed against Gilead’s. Also, there has been news about their talcum powder which has some carcinogenic properties. Also, it is trading close to 20X earnings.


Price:
$116.410
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-06-15 BUY Must be logged in to use chart JPM-N JP Morgan Chase & Co

(Market Call Minute.) If this is one of the banks that you feel you want to own, he wouldn’t have any argument with that.


Price:
$61.970
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-06-15 HOLD Must be logged in to use chart LZB-N La-Z-Boy Inc.

This is a play on the housing recovery, which is very, very nascent. Household formations are still well below historic levels. This company is going to be a beneficiary of that. Very, very well-managed. You are going to see a higher beta on a stock like this, and he would suggest that you stay with this over the long-term, and not be too sensitive to the ups and downs. Thinks it will pay you over time.


Price:
$26.310
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 1,785 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.